Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
Anhui Anke Biotechnology Group Co Ltd
Revenue
Anhui Anke Biotechnology Group Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
|
Revenue
¥2.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
8%
|
CAGR 10-Years
17%
|
|
|
Beigene Ltd
HKEX:6160
|
Revenue
¥17.4B
|
CAGR 3-Years
102%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Revenue
¥9.4B
|
CAGR 3-Years
30%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Revenue
¥2.1B
|
CAGR 3-Years
111%
|
CAGR 5-Years
97%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Revenue
¥2.2B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Revenue
¥1.9B
|
CAGR 3-Years
291%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Anhui Anke Biotechnology Group Co Ltd
Glance View
Anhui Anke Biotechnology Group Co., Ltd., nestled in the heart of China's Anhui Province, weaves a story that blends innovation with a commitment to health. Founded in 1986, Anke Biotechnology made its mark early by focusing on the development and manufacturing of biopharmaceutical products. The company's narrative is rooted in its pursuit of cutting-edge technology, specifically in the fields of genetic engineering, fermentation technology, and vaccine production. As China looks to bolster its biopharmaceutical sector, Anke stands out with its robust pipeline of recombinant protein drugs and vaccines that cater to widespread public health needs. By leveraging advanced bioengineering processes, the company aims to encapsulate scientific complexity into tangible, life-saving treatments. At the core of its operations is a diverse business model that spans research, development, production, and commercialization of healthcare products. Through strategic alliances and continuous investment in R&D, Anke Biotechnology sustains a competitive edge by bringing innovative therapies to market. Revenue flows from its flagship products like recombinant human growth hormones and interferons, which address critical healthcare demands not just within China, but internationally as well. Furthermore, the company astutely capitalizes on the rising healthcare needs of an aging population, along with the increasing importance of preventive medicine, reflected in its vaccine offerings. It’s this strategic acumen, blended with scientific prowess, that allows Anhui Anke Biotechnology to thrive in an industry characterized by rapid innovation and evolving challenges.
See Also
What is Anhui Anke Biotechnology Group Co Ltd's Revenue?
Revenue
2.5B
CNY
Based on the financial report for Dec 31, 2024, Anhui Anke Biotechnology Group Co Ltd's Revenue amounts to 2.5B CNY.
What is Anhui Anke Biotechnology Group Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
17%
Over the last year, the Revenue growth was -12%. The average annual Revenue growth rates for Anhui Anke Biotechnology Group Co Ltd have been 5% over the past three years , 8% over the past five years , and 17% over the past ten years .
You don't have any saved screeners yet